Sign in
ALT Stock Price, Chart, Stats & News
Altimmune, Inc.
Save
230.35M
Market cap
–
Current P/E
8.18x
Forward P/E
ALT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -36387.80% |
Operating margin | -230460.98% |
Pretax margin | -216521.95% |
Net margin | -214860.98% |
Effective tax rate | 0.77% |
ROA | -31.47% |
ROE | -49.35% |
D/E | 0.16x |
Interest coverage ratio | -57.76x |
ALT valuation
P/E | – |
P/S | 6500.90x |
P/B | 1.35x |
P/CF | -4.48x |
P/FCF | -3.93x |
P/OCF | -4.48x |
PEG | -0.62x |
EV multiple | -3.07x |
About
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH).
Similar securities
Based on sector and market capitalization
Report issue